User:Mr. Ibrahem/Zanubrutinib

Zanubrutinib, sold under the brand name Brukinsa, is a medication used for the treatment of mantle cell lymphoma (MCL) which has received prior treatment. It may also be used for lymphoplasmatic lymphoma. It is taken by mouth.

Common side effects include low white blood cells, low platelets, rash, diarrhea, and low hemoglobin. Other side effects may include bleeding, infection, atrial fibrillation, and another cancer. Use during pregnancy may harm the baby. It is a Bruton's tyrosine kinase (BTK) inhibitor and works by slowing tumor growth.

Zanubrutinib was approved for medical use in the United States in 2019. It received an orphan designation in Europe that year as well. In the United States a month of treatment costs about 13,000 USD as of 2021. This amount in China cost about 21,000 RMB (3,250 USD).